Clinical Trial

PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 9, 2023 (before its estimated December 31, 2023 completion). Its status may not reflect the trial's current state.
Summary
This is a non-randomized, open-label, single-center, phase II trial to evaluate the safety and effectiveness of surgery or radiotherapy after PD-L1 inhibitor (TQB2450) and chemotherapy induction therapy followed by maintenance therapy as first-line treatment in patients limited-stage SCLC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2020-09-01; most recent amendment 2023-05-06.
Status change: Not Yet Recruiting → Recruiting 2021-01-25
Trial Details
NCT Number NCT04539977
Lead Sponsor Shanghai Pulmonary Hospital, Shanghai, China
Conditions Small-cell Lung Cancer
Enrollment 40 participants
Start Date 2020-09-01
Primary Completion 2023-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-05-09